Allogene Therapeutics Inc (ALLO) concluded trading on Thursday at a closing price of $1.56, with 2.44 million shares of worth about $3.81 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -41.57% during that period and on March 27, 2025 the price saw a loss of about -0.64%. Currently the company’s common shares owned by public are about 212.21M shares, out of which, 139.53M shares are available for trading.
Stock saw a price change of -4.29% in past 5 days and over the past one month there was a price change of -23.53%. Year-to-date (YTD), ALLO shares are showing a performance of -26.76% which decreased to -63.64% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.32 but also hit the highest price of $4.63 during that period. The average intraday trading volume for Allogene Therapeutics Inc shares is 5.51 million. The stock is currently trading -14.85% below its 20-day simple moving average (SMA20), while that difference is down -16.08% for SMA50 and it goes to -33.98% lower than SMA200.
Allogene Therapeutics Inc (NASDAQ: ALLO) currently have 212.21M outstanding shares and institutions hold larger chunk of about 63.64% of that.
The stock has a current market capitalization of $338.93M and its 3Y-monthly beta is at 0.95. It has posted earnings per share of -$1.34 in the same period. It has Quick Ratio of 8.54 while making debt-to-equity ratio of 0.21. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALLO, volatility over the week remained 6.44% while standing at 9.35% over the month.
Stock’s fiscal year EPS is expected to rise by 9.90% while it is estimated to decrease by -4.62% in next year. EPS is likely to shrink at an annualized rate of -1.15% for next 5-years, compared to annual growth of 6.26% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citizens JMP on March 14, 2025 offering a Mkt outperform rating for the stock and assigned a target price of $5 to it. Coverage by Oppenheimer stated Allogene Therapeutics Inc (ALLO) stock as an Outperform in their note to investors on August 08, 2024, suggesting a price target of $11 for the stock. Stock get a Neutral rating from Guggenheim on January 05, 2024.
